ABSTRACT
I. Background The overall success of transplantation is critically limited by the need for lifelong post-transplant immunosuppression. Antirejection drug regimens, which typically include calcineurin inhibitors, steroids, and antiproliferative agents, inhibit recipient immune responses at the cost of diabetes, renal failure, and cancer. In addition, sustained immunosuppression contributes directly to infection. In lung transplant recipients in particular, infection remains the leading cause of early post-transplant mortality.
